I would say this is one section required to be included in the CER; you don’t need to create a stand-alone report. You still need the state of the art.
Suggested Reading
For subchronic systemic toxicity studied via implantation, what is the basis for determining the implantation… Can products made from materials conforming to YY 0341.1 Appendix B be exempted from biological evaluation? What factors may affect biocompatibility risk when using biological test data from similar devices for… How is the endotoxin limit for wound dressing products determined? What are the key focus areas in the evaluation of acute, subacute, subchronic, and chronic toxicity, and can… How should the evaluation of new items in the endpoint table be considered after the implementation of the new… When combining subchronic and implantation tests in one project, what factors need to be considered, and how can… Do all medical devices require chemical characterization? GB/T 16886.11-2021 adds tests for subchronic systemic toxicity evaluation with dual-route exposure. Which… Under what conditions can the extraction liquid of dressings be accepted after pH adjustment, centrifugation,… GB/T 16886.1-2022 includes implantation in the biological evaluation of dressings. How should implantation tests… Why is the extraction period typically 24 hours in China for cytotoxicity testing?